{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:43:17Z","timestamp":1648849397490},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00120-018-0605-7","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T02:53:13Z","timestamp":1519959193000},"page":"568-576","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Zur urogenitalen Klinik der lokalisierten\/systemischen BCGitis"],"prefix":"10.1007","volume":"57","author":[{"given":"W.\u2011D. U.","family":"B\u00f6hm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Toma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"605_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJH Arends","year":"2016","unstructured":"Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moscovitz B, van der Heijden AG, Witjes JA (2016) Results of a\u00a0randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e8rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69:1046\u20131052","journal-title":"Eur Urol"},{"issue":"3","key":"605_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Hern\u00e1ndez V, Kaasinen E, Palou J, Roupr\u00eat M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461","journal-title":"Eur Urol"},{"key":"605_CR3","volume-title":"Die intravesikale Immuntherapie mit Bacillus-Calmette-Gu\u00e9rin \u2013 Fakten, Vergleich, Ergebnisse","author":"A B\u00f6hle","year":"1998","unstructured":"B\u00f6hle A, Jocham D (1998) Die intravesikale Immuntherapie mit Bacillus-Calmette-Gu\u00e9rin \u2013 Fakten, Vergleich, Ergebnisse. Fischer, Stuttgart, Jena, L\u00fcbeck"},{"key":"605_CR4","first-page":"16","volume":"6","author":"V Demers","year":"2012","unstructured":"Demers V, Peisser V (2012) \u201eBCGitis\u201c: a rare case of tuberculous epididymo-orchitis following intravesical bacillus Calmette-Gu\u00e9rin therapy. J\u00a0Radiol Case Rep 6:16\u201321","journal-title":"J Radiol Case Rep"},{"key":"605_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.eururo.2013.05.027","volume":"64","author":"B Ehclaie","year":"2013","unstructured":"Ehclaie B, Sylvester R, Herr HW (2013) Maintenance bacillus Calmette-Gu\u00e9rin treatment of non-muscle-bladder cancer. A critical evaluation oft he evidence. Eur Urol 64:579\u2013585","journal-title":"Eur Urol"},{"key":"605_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkoli Z, van de Beek C, Gorilia T, de Reijke TM, EORTC Genito-Urinary Tract Cancer Group (2010) Long term efficacy results of EORTC genito-urinary tract cancer group randomized phase 3 study 30911 comparing intravesical instillations of Epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus Isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57:766\u2013773","journal-title":"Eur Urol"},{"key":"605_CR7","unstructured":"Epidemiologisches Bulletin. Robert Koch Institut Berlin, 05. Mai 2006\/Nr.\u00a018"},{"key":"605_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","volume":"190","author":"P Gontero","year":"2013","unstructured":"Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F (2013) The impact of intravesical gemcitabine and 1\/3 dose bacillus Calmette-Gu\u00e9rin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a\u00a0prospective, randomized, phase II trial. J\u00a0Urol 190:857\u2013862","journal-title":"J Urol"},{"key":"605_CR9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/j.1464-410X.2012.11778.x","volume":"111","author":"HW Herr","year":"2013","unstructured":"Herr HW, Dalbagni G (2013) Intravesical bacille Calmette-Guerin(BCG) in immunologically comprimised patients with bladder cancer. BJU Int 111:984\u2013987","journal-title":"BJU Int"},{"key":"605_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1139\/cjpp-2015-0091","volume":"93","author":"K Juszczak","year":"2015","unstructured":"Juszczak K, Maciukiewicz P (2015) The role oft the peripheral cannabinoid system in the pathogenesis of detrusor overactivity evoked by increased intracesical osmolarity in rats. Can J Physiol Pharmacol 93:721\u2013726","journal-title":"Can J Physiol Pharmacol"},{"key":"605_CR11","first-page":"321","volume":"62","author":"K Juszczak","year":"2011","unstructured":"Juszczak K, Ziomber A, Thor PJ (2011) Effect of partial and complete blockade of vanilloid (TRPV1\u20136) and ankyrin (TRPA1) transient receptor potential ion channels on urinary bladder motor activity in an experimental hyperosmolar overactive bladder rat model. J\u00a0Physiol Pharmacol 62:321\u2013326","journal-title":"J Physiol Pharmacol"},{"key":"605_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1055\/s-0035-1552115","volume":"187","author":"S Kaufmann","year":"2015","unstructured":"Kaufmann S, Amend B, Kruck S, Gakis G, Bedke J, Horger M (2015) Imaging findings in BCGitis. Bacillus-Calmette-Gu\u00e9rin-Infektion (BCGitis) nach intravesikaler BCG-Instillationstherapie bei Urothelkarzinom der Harnblase. Fortschr Geb Rontgenstrahlen Neuen Bildgeb Verfahr Erganzungsbd 187:623\u2013626","journal-title":"Fortschr. Geb. Rontgenstrahlen Neuen. Bildgeb Verfahr Erganzungsbd"},{"key":"605_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00120-016-0234-y","volume":"56","author":"S Lebentrau","year":"2017","unstructured":"Lebentrau S, May M, Weckermann D, Speck T, Wick A\u2011K, Mathew M, Schostak M (2017) Nicht- muskelinvasives Harnblasenkarzinom: Risikostratefizierung und Befundweitergabe. Ergebnisse einer Fragebogenstudie und Vorstellung einer Softwarel\u00f6sung. Urologe 56:194\u2013201","journal-title":"Urologe"},{"issue":"4","key":"605_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/02656736.2016.1155760","volume":"32","author":"EI Liem","year":"2016","unstructured":"Liem EI, Crezee H, de la Rosette JJ, de Reijke TM (2016) Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperthermia 32(4):363\u2013373","journal-title":"Int J Hyperthermia"},{"key":"605_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","volume":"68","author":"L Martinez-Pineiro","year":"2015","unstructured":"Martinez-Pineiro L, Portillo JA, Fernandez JM, Zabala JA, Cadierno I, Moyano JL, Soisona E, Undo M, Beardo P, Rodriguez-Molina J, Chantada V, Palou J, Muntanola P, Alonso-Dorrego JM, Perez-Garcia FJ, Silva JM, Chesa N, Montesinos M, Ojea A, Madero R, Martinez-Pineiro JA (2015) Maintenance therapy with 3\u2011monthly bacillus Calmette-Gu\u00e8rin for 3 jears is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol 68:256\u2013262","journal-title":"Eur Urol"},{"key":"605_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors. J\u00a0Urol 116:180\u2013183","journal-title":"J Urol"},{"key":"605_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, Collette S, Oesterlinck W (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta T1 papillary carcinoma oft the urinary bladder: one-third dose versus full dose and 1 year versus 3 jears of maintenance. Eur Urol 63:462\u2013472","journal-title":"Eur Urol"},{"key":"605_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"JR Oddens","year":"2016","unstructured":"Oddens JR, Sylvester RJ, Brausi MA et al (2016) Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Gu\u00e9rin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. BJU Int 118:423\u2013428","journal-title":"BJU Int"},{"key":"605_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1590\/S1806-37132015000000126","volume":"41","author":"MJ Oliveira","year":"2015","unstructured":"Oliveira MJ, Vaz D, Carvalho A, Braga R, Duarte R (2015) BCGitis: a rare complication after intravesical BCG therapy. J\u00a0Bras Pneumol 41:480\u2013481","journal-title":"J Bras Pneumol"},{"key":"605_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/MD.0000000000000119","volume":"93","author":"MA Perez-Jacoiste Asin","year":"2014","unstructured":"Perez-Jacoiste Asin MA, Fernandez-Ruiz M, Lopez-Medrano F, Lumbreras C, Tejido A, San Juan R, Arrebola-Pajares A, Lizasoain M, Prieto S, Aquado JM (2014) Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors and outcome in a\u00a0single-institution series and review oft the literature. Medicine (Baltimore) 93:236\u2013254","journal-title":"Medicine (Baltimore)"},{"key":"605_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3109\/23744235.2015.1055794","volume":"47","author":"JD Pommier","year":"2015","unstructured":"Pommier JD, Ben Lasfar N, Van Grunderbeeck N, Burdet C, Laouenan C, Rioux C, Pierre-Audigier C, Meybeck A, Choudat L, Benchikh A, Nguyen S, Bouvet E, Yeni P, Yazdanpanah Y, Joly V (2015) Complications following intravesical bacillus Calmette-Gu\u00e9rin treatment for bladder cancer: a\u00a0case series of 22 patients. Infect Dis (Lond) 47:725\u2013731","journal-title":"Infect Dis (Lond)"},{"key":"605_CR22","unstructured":"S3-Leitlinie Fr\u00fcherkennung, Diagnostik, Therapie und Nachsorge des Harnblasenkarzinoms. Langversion 1.1 \u2013 November 2016, \u00a9Leitlinienprogramm Onkologie, AWMF-Registr.-Nr.\u00a0032\/038OL"},{"key":"605_CR23","first-page":"133","volume":"66","author":"T Schaberg","year":"2012","unstructured":"Schaberg T, Bauer T, Castell S, Dalhoff K, Detjen A, Diel R, Greinert U, Hauer B, Lange C, Magdorf K, Loddenkemper R (2012) Empfehlungen zur Therapie, Chemopr\u00e4vention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter. Deutsches Zentralkomitee zur Bek\u00e4mpfung der Tuberkulose (DZK), Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP). Pulmologie 66:133\u2013171","journal-title":"Pulmologie"},{"key":"605_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1152\/advan.00080.2016","volume":"40","author":"DU Silverthorn","year":"2016","unstructured":"Silverthorn DU (2016) Isosmotic is not always isotonic: the five-minute version. Adv Physiol Educ 40:499\u2013500","journal-title":"Adv Physiol Educ"},{"key":"605_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000471561","volume":"16","author":"A Steg","year":"1989","unstructured":"Steg A, Leleu C, Debr\u00e9 B, Boccon-Gibod L, Sicard DG (1989) Systemic bacillus Calmette-Gu\u00e9rin infection, \u201eBCGitis\u201c, in patients treated by intravesical bacillus Calmette-Gu\u00e9rin therapy for bladder cancer. Eur Urol 16:161\u2013164","journal-title":"Eur Urol"},{"key":"605_CR26","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.juro.2013.04.120","volume":"190","author":"IA Sternberg","year":"2013","unstructured":"Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW (2013) Intravesical Gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure. J\u00a0Urol 190:1686\u20131691","journal-title":"J Urol"},{"key":"605_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00508-013-0343-1","volume":"125","author":"N Swietek","year":"2013","unstructured":"Swietek N, Waldert M, Susani M, Schatzl G, Klatte T (2013) Intravesical bacillus Calmette-Gu\u00e9rin instillation therapy for non-muscle-invasive bladder cancer following solid organ transplantation. Wien Klin Wochenschr 125:189\u2013195","journal-title":"Wien Klin Wochenschr"},{"key":"605_CR28","volume-title":"Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: an interim analysis of 307 patients","author":"WS Tan","year":"2017","unstructured":"Tan WS, Palou J, Kelly J (2017) Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: an interim analysis of 307 patients. 32nd Annual EAU Congress, London, 24.\u201328.03.2017 (Abstract 662)"},{"key":"605_CR29","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","volume":"157","author":"PD Vegt","year":"1997","unstructured":"Vegt PD, van der Mejden AP, van der Sylvester R, Brausi M, H\u00f6ltl W, de Balincourt C (1997) Does isoniazid reduce side effects of intravesical bacillus Calmette Gu\u00e9rin therapy in superficial bladder cancer ? Interim results of European Organization for Research and Treatment of Cancer Protokoll 30911. J\u00a0Urol 157:1246\u20131249","journal-title":"J Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-018-0605-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-018-0605-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-018-0605-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T20:07:11Z","timestamp":1551470831000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-018-0605-7"}},"subtitle":["Retrospektive Untersuchungen im direkten Vergleich zu Mitomycin\u00a0C"],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1007\/s00120-018-0605-7","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"2 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"W.-D.\u00a0U.\u00a0B\u00f6hm, R.\u00a0Koch, S.\u00a0Wenzel, M.P.\u00a0Wirth und M.\u00a0Toma geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}